Aerovate Therapeutics Stock Probability of Future Stock Price Finishing Over 2.53

AVTE Stock  USD 2.60  0.04  1.56%   
Aerovate Therapeutics' future price is the expected price of Aerovate Therapeutics instrument. It is based on its current growth rate as well as the projected cash flow expected by the investors. This tool provides a mechanism to make assumptions about the upside potential and downside risk of Aerovate Therapeutics performance during a given time horizon utilizing its historical volatility. Check out Aerovate Therapeutics Backtesting, Aerovate Therapeutics Valuation, Aerovate Therapeutics Correlation, Aerovate Therapeutics Hype Analysis, Aerovate Therapeutics Volatility, Aerovate Therapeutics History as well as Aerovate Therapeutics Performance.
For information on how to trade Aerovate Stock refer to our How to Trade Aerovate Stock guide.
  
At present, Aerovate Therapeutics' Price To Book Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Fair Value is expected to grow to 5.72, whereas Price Earnings To Growth Ratio is forecasted to decline to (0.23). Please specify Aerovate Therapeutics' target price for which you would like Aerovate Therapeutics odds to be computed.

Aerovate Therapeutics Target Price Odds to finish over 2.53

The tendency of Aerovate Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current PriceHorizonTarget PriceOdds to stay above $ 2.53  in 90 days
 2.60 90 days 2.53 
about 31.51
Based on a normal probability distribution, the odds of Aerovate Therapeutics to stay above $ 2.53  in 90 days from now is about 31.51 (This Aerovate Therapeutics probability density function shows the probability of Aerovate Stock to fall within a particular range of prices over 90 days) . Probability of Aerovate Therapeutics price to stay between $ 2.53  and its current price of $2.6 at the end of the 90-day period is about 8.57 .
Given the investment horizon of 90 days Aerovate Therapeutics has a beta of 0.67. This suggests as returns on the market go up, Aerovate Therapeutics average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Aerovate Therapeutics will be expected to be much smaller as well. Additionally Aerovate Therapeutics has an alpha of 0.4848, implying that it can generate a 0.48 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta).
   Aerovate Therapeutics Price Density   
       Price  

Predictive Modules for Aerovate Therapeutics

There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Aerovate Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Aerovate Therapeutics' price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Hype
Prediction
LowEstimatedHigh
0.122.405.95
Details
Intrinsic
Valuation
LowRealHigh
2.3010.0013.55
Details
4 Analysts
Consensus
LowTargetHigh
29.1232.0035.52
Details
Earnings
Estimates (0)
LowProjected EPSHigh
-0.65-0.63-0.61
Details

Aerovate Therapeutics Risk Indicators

For the most part, the last 10-20 years have been a very volatile time for the stock market. Aerovate Therapeutics is not an exception. The market had few large corrections towards the Aerovate Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Aerovate Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Aerovate Therapeutics within the framework of very fundamental risk indicators.
α
Alpha over Dow Jones
0.48
β
Beta against Dow Jones0.67
σ
Overall volatility
0.27
Ir
Information ratio 0.14

Aerovate Therapeutics Alerts and Suggestions

In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Aerovate Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Aerovate Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.
Aerovate Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (75.52 M) with profit before overhead, payroll, taxes, and interest of 0.
Aerovate Therapeutics currently holds about 151.99 M in cash with (56.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Aerovate Therapeutics has a frail financial position based on the latest SEC disclosures
Over 100.0% of the company shares are held by institutions such as insurance companies
Latest headline from gurufocus.com: HAREHOLDER ALERT The MA Class Action Firm Continues To Investigate Merger - AVTE, BCOV, ...

Aerovate Therapeutics Price Density Drivers

Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Aerovate Stock often depends not only on the future outlook of the current and potential Aerovate Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Aerovate Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding26.3 M
Cash And Short Term Investments122.4 M

Aerovate Therapeutics Technical Analysis

Aerovate Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Aerovate Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Aerovate Therapeutics. In general, you should focus on analyzing Aerovate Stock price patterns and their correlations with different microeconomic environments and drivers.

Aerovate Therapeutics Predictive Forecast Models

Aerovate Therapeutics' time-series forecasting models is one of many Aerovate Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Aerovate Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.

Things to note about Aerovate Therapeutics

Checking the ongoing alerts about Aerovate Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Aerovate Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Aerovate Therapeutics had very high historical volatility over the last 90 days
Net Loss for the year was (75.52 M) with profit before overhead, payroll, taxes, and interest of 0.
Aerovate Therapeutics currently holds about 151.99 M in cash with (56.78 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 6.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Aerovate Therapeutics has a frail financial position based on the latest SEC disclosures
Over 100.0% of the company shares are held by institutions such as insurance companies
Latest headline from gurufocus.com: HAREHOLDER ALERT The MA Class Action Firm Continues To Investigate Merger - AVTE, BCOV, ...
When determining whether Aerovate Therapeutics is a strong investment it is important to analyze Aerovate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Aerovate Therapeutics' future performance. For an informed investment choice regarding Aerovate Stock, refer to the following important reports:
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aerovate Therapeutics. If investors know Aerovate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aerovate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(2.99)
Return On Assets
(0.49)
Return On Equity
(0.82)
The market value of Aerovate Therapeutics is measured differently than its book value, which is the value of Aerovate that is recorded on the company's balance sheet. Investors also form their own opinion of Aerovate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Aerovate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aerovate Therapeutics' market value can be influenced by many factors that don't directly affect Aerovate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aerovate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Aerovate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aerovate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.